A brief overview of biosimilars and factors limiting their uptake.
作者信息
Sosulski Nicholas
机构信息
The author was a second-year PharmD student in the Faculty of Pharmacy at the University of British Columbia at the time this piece was written. In addition to his studies, he currently works as a pharmacy assistant at Shoppers Drug Mart and aspires to practise in the hospital environment.
出版信息
Can Pharm J (Ott). 2019 Oct 14;152(6):364-366. doi: 10.1177/1715163519879411. eCollection 2019 Nov-Dec.
Abstract
摘要
相似文献
1
A brief overview of biosimilars and factors limiting their uptake.生物类似药概述及其应用受限因素
Can Pharm J (Ott). 2019 Oct 14;152(6):364-366. doi: 10.1177/1715163519879411. eCollection 2019 Nov-Dec.
2
Policies for biosimilar uptake in Europe: An overview.欧洲生物类似药采用政策概述
PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017.
3
Biosimilars in Developed Economies: Overview, Status, and Regulatory Considerations.生物类似药在发达经济体中的发展：概述、现状与监管考量。
Regul Toxicol Pharmacol. 2020 Feb;110:104525. doi: 10.1016/j.yrtph.2019.104525. Epub 2019 Nov 16.
4
Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.患者可及性、未满足的医疗需求、预期获益以及对东欧国家生物类似药使用的关注：专家调查。
Biomed Res Int. 2018 Jan 10;2018:9597362. doi: 10.1155/2018/9597362. eCollection 2018.
5
A Comprehensive Overview on Biosimilars.生物类似药综合概述
Curr Protein Pept Sci. 2016;17(8):756-761. doi: 10.2174/1389203717666160226144618.
6
Biosimilar uptake by British local formularies: a cross sectional study.英国地方药品目录中生物类似药的使用情况：一项横断面研究。
Int J Clin Pharm. 2017 Oct;39(5):1055-1060. doi: 10.1007/s11096-017-0523-6. Epub 2017 Sep 4.
7
Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.生物类似药与专利生物药之间的竞争：借鉴欧洲和日本的经验
Pharmacoeconomics. 2016 Nov;34(11):1173-1186. doi: 10.1007/s40273-016-0428-6.
8
Optimizing use and addressing challenges to uptake of biosimilars.优化生物类似药的使用并解决其采用面临的挑战。
Am J Manag Care. 2018 Nov;24(21 Suppl):S457-S461.
9
Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.评价俄罗斯医生对生物类似药的知识和态度，以及与处方相关的问题。
Biomolecules. 2019 Feb 11;9(2):57. doi: 10.3390/biom9020057.
10
Current and future roles of biosimilars in oncology practice.生物类似药在肿瘤学实践中的当前及未来作用。
Oncol Lett. 2020 Jan;19(1):45-51. doi: 10.3892/ol.2019.11105. Epub 2019 Nov 15.
引用本文的文献
1
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.中国免疫介导炎症性疾病中生物类似药与参照生物制剂的临床获益、成本及采用情况评估。
Front Public Health. 2024 Dec 4;12:1476213. doi: 10.3389/fpubh.2024.1476213. eCollection 2024.
2
Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis.安抚技巧对银屑病生物类似药信心无显著影响：一项针对自我认定为银屑病患者的便利样本调查
Dermatol Ther (Heidelb). 2022 Sep;12(9):2173-2180. doi: 10.1007/s13555-022-00781-3. Epub 2022 Jul 28.
本文引用的文献
1
The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.《生物类似药的反安慰剂效应？双盲与开放标签研究的系统评价》
J Manag Care Spec Pharm. 2018 Oct;24(10):952-959. doi: 10.18553/jmcp.2018.24.10.952.
2
To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.见或不见：关于非安慰剂效应的争论和优化生物类似药的使用。
Adv Ther. 2018 Jun;35(6):749-753. doi: 10.1007/s12325-018-0719-8. Epub 2018 Jun 5.
3
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.开放性、非强制性由依那西普原研药转换为生物类似药 SB4：一项对照队列研究的 6 个月结果。
Arthritis Rheumatol. 2018 Sep;70(9):1408-1418. doi: 10.1002/art.40516. Epub 2018 Aug 6.
4
The nocebo effect challenges the non-medical infliximab switch in practice.在实际应用中，反安慰剂效应给英夫利昔单抗的非医学转换带来了挑战。
Eur J Clin Pharmacol. 2018 May;74(5):655-661. doi: 10.1007/s00228-018-2418-4. Epub 2018 Jan 24.
5
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.生物类似药的治疗效果：谨防反安慰剂效应。
Rheumatol Ther. 2017 Dec;4(2):209-218. doi: 10.1007/s40744-017-0085-z. Epub 2017 Oct 14.
6
Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.原研生物制剂和生物类似药的认知：一项在比利时类风湿关节炎患者和风湿病学家中的调查。
BioDrugs. 2017 Oct;31(5):447-459. doi: 10.1007/s40259-017-0244-3.
7
Biosimilars: Implications for Clinical Practice.生物类似药：对临床实践的影响。
J Oncol Pract. 2017 Sep;13(9_suppl):24s-31s. doi: 10.1200/JOP.2017.025734.
8
The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.生物制品和生物类似药在美国日益重要的作用：来自美国药师协会生物制品和生物类似药利益相关者会议的观点
J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):e15-e27. doi: 10.1016/j.japh.2017.05.014. Epub 2017 Jul 6.
9
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.从原研英夫利昔单抗转换为生物类似药 CT-P13 与继续使用原研英夫利昔单抗维持治疗（NOR-SWITCH）：一项 52 周、随机、双盲、非劣效性试验。
Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11.
10
Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.评估德国各地胃肠病学家和患者对溃疡性结肠炎和克罗恩病生物类似药的接受度。
PLoS One. 2017 Apr 14;12(4):e0175826. doi: 10.1371/journal.pone.0175826. eCollection 2017.
Zotero 插件